Vanessa N. Raabe

Dr. Vanessa N. Raabe


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
MMMark J. Mulligan
Mark J. Mulligan
KLKirsten E. Lyke
Kirsten E. Lyke
NKNicholas Kitchin
Nicholas Kitchin
JAJudith Absalon
Judith Absalon
AGAlejandra Gurtman
Alejandra Gurtman
KJKathrin U. Jansen
Kathrin U. Jansen

12 April 2019 in Microbiology Spectrum
Verified
Journal Article
Closed access
VRVanessa N. Raabe
Vanessa N. Raabe
ASAndi L Shane
Andi L Shane
Invasive disease due to group B Streptococcus infection ( Streptococcus agalactiae ) results in a wide spectrum of clinical disease. In North America, serotypes Ia, Ib, II, III, and V are most frequently associated with invasive disease. Group B Streptococcus remains a continuing source of morbidity and mortality in high-risk populations, including pregnant women, neonates, and the elderly; an increasing incidence of invasive disease has been observed in nonpregnant adults. Group B Streptococcus remains the most common culture-confirmed neonatal bacterial infection in the United States and is a significant source of neonatal morbidity globally. Intrapartum antibiotic prophylaxis has reduced the incidence of early-onset neonatal disease without a notable impact on the incidence of late-onset neonatal disease. Penicillin G remains the mainstay of therapy, although reduced penicillin susceptibility has been observed in select isolates. Increased frequency of resistance to non-beta-lactam antibiotics, including clindamycin, erythromycin, and fluoroquinolones, has been observed, with some isolates demonstrating resistance to vancomycin. The development and implementation of strategies to identify hosts, treat judiciously with antimicrobials with the narrowest spectra, and prevent invasive disease, with vaccines, are essential to reduce the burden of group B Streptococcus disease.

16 January 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
DBDaniel L. Barber
Daniel L. Barber
SSShunsuke Sakai
Shunsuke Sakai
RKRagini R. Kudchadkar
Ragini R. Kudchadkar
SFSteven P. Fling
Steven P. Fling
TDTracey A. Day
Tracey A. Day
ESElad Sharon
Elad Sharon
Increased Mtb-specific T H 1 responses precede tuberculosis associated with PD-1 blockade.

22 June 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
VRVanessa N. Raabe
Vanessa N. Raabe
GKGerrit Kann
Gerrit Kann
BRBruce S Ribner
Bruce S Ribner
AMAndres Morales
Andres Morales
JVJay B Varkey
Jay B Varkey
TWTimo Wolf
Timo Wolf
Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged detectable virus RNA in blood and semen, suggesting that the possibility of sexual transmission of Lassa virus should be considered.

1 July 2016 in Journal of Clinical Virology
Verified
Journal Article
Closed access
NSNirav S. Shah
Nirav S. Shah
JGJared A. Greenberg
Jared A. Greenberg
MMMoira C. McNulty
Moira C. McNulty
KGKevin S. Gregg
Kevin S. Gregg
JRJames Riddell
James Riddell
Michael Z. DavidMichael Z. David
Michael Z. David

1 July 2020 in The Lancet
Verified
Journal Article
Closed access
SSSheila Shaigany
Sheila Shaigany
MGMarlis Gnirke
Marlis Gnirke
AGAllison Guttmann
Allison Guttmann
HCHong Chong
Hong Chong
SMShane Meehan
Shane Meehan
AFAlisa Femia
Alisa Femia